What are FDA's RTCT and how do they differ from traditional clinical trial monitoring?

FDA's RTCT allow agency reviewers to access pre-agreed safety and efficacy signals as a trial is actively running, eliminating the traditional wait for sponsors to collect, clean, and submit data through the conventional review cycle. Unlike standard clinical data management workflows, RTCT enables continuous data transmission directly to FDA, as demonstrated by two oncology proof-of-concept studies already live in 2026.

What are the biggest unresolved challenges in FDA's real-time clinical trial initiative?

Key open questions in RTCT include how continuous data review affects blinding and statistical multiplicity control in adaptive trial design, whether FDA has sufficient reviewer capacity to act on streaming data rather than finished study reports, and how accountability is assigned when data flows around a sponsor rather than through it. These regulatory strategy and clinical trial design questions remain critical for sponsors evaluating participation.

How could real-time clinical trial management systems impact drug development timelines and the FDA drug approval process?

RTCT has the potential to compress drug development timelines by giving FDA reviewers earlier visibility into safety and efficacy signals, potentially enabling faster go/no-go decisions and reducing post-submission review lag. However, experts caution that if the true bottleneck in the FDA drug approval process is interpreting ambiguous data rather than transmitting it, the timeline gains may be more limited than anticipated.

What should pharmaceutical sponsors do now to prepare for FDA's real-time clinical trial requirements?

Sponsors should assess their current clinical data management infrastructure, real-time clinical trial management systems, and data safety monitoring board protocols to identify gaps before engaging with FDA's RTCT pilot. Given the number of unresolved regulatory and operational questions, Axtria recommends a measured, well-informed approach, calibrating investment to the initiative's current stage rather than overhauling R&D operations preemptively.

Clinical Trials

The Agentic Intelligence Layer: Unifying Clinical Trial Operations Across Disparate Platforms

Download White Paper

How an agentic AI integration layer turns siloed clinical trial investments into one audit-ready platform

Study sponsors have invested heavily across clinical trial operations platforms, and each delivers real value on its own. They just don't talk to each other. Biomarker signals never reach site selection models. Regulatory teams manually reconcile data across systems that don't share a schema. The technology stack is sophisticated. The value between platforms goes unrealized.

What Fragmentation Actually Costs

Clinical research is expensive: Clinical phases eat roughly 69% of total R&D cash costs; oncology trials run $183,000 to $246,000 per patient; 88% of drugs entering trials never reach approval. Median cost to bring one medicine to market: $708 million.
Recruitment and retention suffer: 85% of trials have retention problems, 30% of patients drop out, and two-thirds of sites miss enrollment targets. These are operational failures, not scientific ones, trial-matching intelligence never reconciles against live CTMS data.
Compliance risk compounds: Manual handoffs between systems break the audit chain, right as ICH E6(R3) extends GxP audit-trail requirements to decentralized trial technology.

A Three-Tier Integration Architecture

Integration: Bi-directional connectors across the vendor stack, with every event structured, queryable, and CDISC/HL7 FHIR-aligned from day one, already in the format regulators require.
Orchestration: Agents execute the routine cross-vendor workflows, enrollment monitoring, biomarker-triggered protocol updates, eCOA anomaly response, submission-ready status packs with GxP audit trails and human-approval checkpoints built in by default.
Natural language interface: Clinical scientists and program leads query the entire pipeline in plain English instead of navigating between vendor dashboards or waiting on manual data pulls.

Built for GxP From the Start

Every automated workflow includes a structured human-approval checkpoint. A named agentic strategy lead owns the LLM governance framework and KPI definitions; dedicated agile delivery teams design every connector for ICH E6 and GxP compliance from the outset. Compliance is a structural feature of the system, available for audit at any point.

Key Takeaways

Consolidating onto fewer vendors sacrifices the specialist capabilities that make leading platforms valuable; the fix is an integration layer above the stack, not fewer platforms.
A three-tier architecture with data connectors, orchestration agents, and natural language interface converts parallel investments into one intelligent pipeline.
GxP compliance and human-in-the-loop checkpoints are designed in from tier one, not bolted on after.
The component technologies are production-ready today. What's been missing is the delivery model that combines clinical operations expertise, agile PMO discipline, and GxP governance.